T-cell modulatory multimeric polypeptides and methods of use thereof
The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
1. A variant IL-2 polypeptide comprising an amino acid sequence having the amino acid sequence set forth in SEQ ID NO:44, wherein amino acid 16 is Ala and amino acid 42 is Ala.
2. A plurality of variant IL-2 polypeptides according to claim 1 , wherein the plurality comprises a first variant IL-2 polypeptide and a second variant IL-2 polypeptide, and wherein the first and second variant IL-2 polypeptides are joined by a linker.
3. A pharmaceutical composition comprising an IL-2 variant according to claim 1 .
4. A nucleic acid comprising a nucleotide sequence encoding the IL-2 variant of claim 1 .
5. A host cell genetically modified with the nucleic acid of claim 4 .
6. A method of making the IL-2 variant, the method comprising culturing a host cell according to claim 5 under conditions such that the genetically modified host cell produces the IL-2 variant.
7. A method of treating an individual comprising administering a therapeutically effective amount of an IL-2 variant according to claim 1 .
8. A fusion polypeptide comprising:
a) a variant IL-2 polypeptide comprising an amino acid sequence having the amino acid sequence set forth in SEQ ID NO:44, wherein amino acid 16 is Ala and amino acid 42 is Ala; and
b) a heterologous fusion partner, wherein the heterologous fusion partner does not comprise a major histocompatibility complex (MHC) polypeptide.
9. A fusion polypeptide comprising:
a) a plurality of variant IL-2 polypeptides, wherein the plurality comprises a first variant IL-2 polypeptide and a second variant IL-2 polypeptide, each variant IL-2 polypeptide comprising an amino acid sequence having the amno acid sequence set forth in SEQ ID NO:44, wherein amino acid 16 is Ala and amino acid 42 is Ala, and wherein the first and second variant IL-2 polypeptides are joined by a linker; and
b) a heterologous fusion partner, wherein the heterologous fusion partner does not comprise a major histocompatibility complex (MHC) polypeptide.
10. A fusion polypeptide of claim 8 , wherein the heterologous fusion partner is fused to the N-terminus or C-terminus of the variant IL-2 polypeptide, and wherein a linker may be interposed between the heterologous fusion partner and variant IL-2 polypeptide.
11. A fusion polypeptide of claim 8 , wherein the heterologous fusion partner is an antibody Fc region.
12. A fusion polypeptide of claim 8 , wherein the heterologous fusion partner is an antigen-binding region of an antibody.
13. A pharmaceutical composition comprising a fusion polypeptide according to claim 8 .
14. A nucleic acid comprising a nucleotide sequence encoding a fusion polypeptide according to claim 8 .
15. A host cell genetically modified with the nucleic acid of claim 14 .
16. A method of making a fusion polypeptide, the method comprising culturing a host cell according to claim 15 under conditions such that the genetically modified host cell produces the fusion polypeptide.
17. A method of treating an individual comprising administering a therapeutically effective amount of a fusion polypeptide according to claim 8 .
18. A method of treating an individual comprising administering a therapeutically effective amount of a fusion polypeptide according to claim 11 .